For research use only. Not for therapeutic Use.
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D)[1][2].
Volagidemab (5 mg/kg, s.c.) suppresses type 1 diabetes phenotype in Alloxan-induced diabetic mice[2].
| Catalog Number | I042214 |
| CAS Number | 1233956-13-2 |
| Purity | ≥95% |
| Reference | [1]. Pettus J, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 Oct;28(10):2092-2099. [2]. Wang MY, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2503-8. |
